OTCMKTS:HCYTD

H-CYTE - HCYTD Competitors

$2.02

-1.98 (-49.50%)

(As of 07/11/2022)

Add

Compare

Today's Range: $2.02
▼
$2.77
50-Day Range: $0.02
▼
$4.00
52-Week Range: $2.02
▼
$77.00

Volume: 400 shs
Average Volume: 103 shs
Market Capitalization: $521,160.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

HCYTD vs. RGIN, BIPHD, ACAI, VRSEF, CRRVF, HDII, USAQ, VGLS, RSPI, and ARGSQ

Should you be buying H-CYTE stock or one of its competitors? The main competitors of H-CYTE include Regenicin (RGIN), Safeplus International (BIPHD), Safeplus International (ACAI), Verisante Technology (VRSEF), CVR Medical (CRRVF), Hypertension Diagnostics (HDII), QHSLab (USAQ), VG Life Sciences (VGLS), RespireRx Pharmaceuticals (RSPI), and Argos Therapeutics (ARGSQ). These companies are all part of the "medical" sector.

H-CYTE vs.

H-CYTE (OTCMKTS:HCYTD) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

: Regenicin received 81 more outperform votes than H-CYTE when rated by MarketBeat users.
Company Underperform Outperform
H-CYTE N/A N/A
Regenicin Outperform Votes
81
69.83%
Underperform Votes
35
30.17%
: 0.0% of Regenicin shares are owned by institutional investors. 5.2% of H-CYTE shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: In the previous week, H-CYTE's average media sentiment score of 0.00 equaled Regenicin's average media sentiment score.
Company Overall Sentiment
H-CYTE Neutral
Regenicin Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
H-CYTE
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Regenicin
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Regenicin has lower revenue, but higher earnings than H-CYTE.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
H-CYTE $1.61 million 0.32 -$4.80 million N/A N/A
Regenicin N/A N/A -$670 thousand N/A N/A
: H-CYTE has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Regenicin has a beta of -2.47, meaning that its share price is 347% less volatile than the S&P 500.
: Regenicin has a net margin of 0.00% compared to H-CYTE's net margin of -450.40%.
Company Net Margins Return on Equity Return on Assets
H-CYTE -450.40% N/A -777.68%
Regenicin N/A N/A -12,737.23%

Company	Underperform	Outperform
H-CYTE	N/A	N/A
Regenicin	Outperform Votes 81 69.83%	Underperform Votes 35 30.17%

Company	Overall Sentiment
H-CYTE	Neutral
Regenicin	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
H-CYTE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Regenicin	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A
Regenicin	N/A	N/A	-$670 thousand	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
H-CYTE	-450.40%	N/A	-777.68%
Regenicin	N/A	N/A	-12,737.23%

Summary

H-CYTE and Regenicin tied by winning 4 of the 8 factors compared between the two stocks.

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCYTD vs. The Competition

Export to Excel

Metric	H-CYTE	Surgical & medical instruments Industry	Medical Sector	OTCMKTS Exchange
Market Cap	$521,000.00	$3.37B	$4.41B	$6.48B
Dividend Yield	N/A	1.55%	7.26%	35.51%
P/E Ratio	N/A	26.06	123.55	1.85
Price / Sales	0.32	67.27	2,950.75	1,206.27
Price / Cash	N/A	41.40	22.89	19.99
Price / Book	-0.06	5.83	6.46	6.03
Net Income	-$4.80M	$85.56M	$166.90M	$726.41M
7 Day Performance	N/A	4.44%	4.70%	1.81%
1 Month Performance	N/A	11.84%	10.80%	6.27%
1 Year Performance	N/A	-26.20%	-27.19%	79.93%

H-CYTE Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGIN Regenicin	0 of 5 stars	$0.00 flat	N/A	N/A	$523,000.00	N/A	0.00	3	Gap Up
BIPHD Safeplus International	0 of 5 stars	$0.07 flat	N/A	-66.5%	$382,000.00	N/A	0.00	N/A
ACAI Safeplus International	0 of 5 stars	$0.07 flat	N/A	-52.8%	$382,000.00	N/A	0.00	2
VRSEF Verisante Technology	0 of 5 stars	$0.03 flat	N/A	N/A	$257,000.00	N/A	0.00	N/A
CRRVF CVR Medical	0 of 5 stars	$0.01 flat	N/A	N/A	$1.01M	N/A	-0.50	N/A
HDII Hypertension Diagnostics	0 of 5 stars	$0.01 flat	N/A	-61.0%	$1.15M	N/A	0.00	2,017	News Coverage Gap Up High Trading Volume
USAQ QHSLab	0 of 5 stars	$0.20 -4.8%	N/A	-74.1%	$1.76M	$1.41M	0.00	3	News Coverage Gap Up
VGLS VG Life Sciences	0 of 5 stars	N/A	N/A	-93.3%	$512,000.00	N/A	0.00	1	High Trading Volume
RSPI RespireRx Pharmaceuticals	0 of 5 stars	$0.00 flat	N/A	-79.7%	$538,000.00	N/A	0.00	2
ARGSQ Argos Therapeutics	0 of 5 stars	$0.05 flat	N/A	N/A	$572,000.00	$1.90M	0.00	21

This page (OTCMKTS:HCYTD) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms